Veracyte has published new data confirming the analytical validity of its Envisia Genomic Classifier to help diagnose idiopathic pulmonary fibrosis.

Its study, “Analytical performance of Envisia: a genomic classifier for usual interstitial pneumonia,” appeared in the journal BMC Pulmonary Medicine.

The 190-gene Envisia Genomic Classifier helps physicians distinguish between IPF and other interstitial lung diseases (ILDs) without the need for invasive, risky and costly surgery. It uses samples obtained through bronchoscopy to make an IPF or ILD diagnosis, achieving highly accurate, reproducible and reliable results across a broad range of conditions and variables.